Please complete the form below to order your FREE Blissel®(estriol50micrograms/g) VAGINAL GEL
placebo demonstration pack.
The kit contains:

  • Applicator
  • Placebo gel
  • QR code links for access to Blissel® Summary of Product Characteristics and Patient Information Leaflets.

 Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com 

How BlisselⓇ
Works

Efficacy

Dosing

Ultra low dose estriol vaginal gel1,2

1.Blissel 50 micrograms/g vaginal gel. Summary of product characteristics. 2.Cano A, et al. Menopause. 2012;19(10):1130-9.

Date of preparation: February 2026 | UK-BLS-672

BlisselⓇ (Estriol 50 Micrograms/G Vaginal Gel)
Safety Information:

CLOSE X


  • For the treatment of postmenopausal vaginal atrophy symptoms, local estrogen therapy should only be initiated for symptoms that adversely affect quality of life.
  • BlisselⓇ 50 micrograms/g vaginal gel must not be combined with estrogen preparations for systemic treatment, as there are no studies of safety and risks with estrogen concentrations attained in combination treatment.
  • Intravaginal applicator may cause minor local trauma, especially in women with serious vaginal atrophy.
  • Before estriol treatment is initiated or reinstituted, a complete personal and family medical history should be taken. Physical (including pelvic and breast) examination should be guided by this and by the contraindications and warnings for use.

Please refer to the Summary of Product Characteristics before prescribing.1

1. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.

Common (≥1/100 to <1/10) and (≥1/1000 to <1/100) undesirable effects1


Date of preparation: April 2026 Item code: UK-BLS-671(1)